SSTR (Somatostatin Receptor)

The current literature on FGF23 transmitted tumors in the cervical spine includes six cases treated with definitive local therapy. This case suggests an alternative option for unresectable FGF23 transmitted tumor in the vertebrae, causing spinal myelopathy.

Although emergency surgery was associated with limited preoperative staging and higher proportion of R2 resections, no statistically significant differences in overall survival, recurrence-free survival, carcinoid symptom resolution or local complications were observed. However, these results need to be interpreted cautiously due to the small sample size of the study.

[177Lu]-Lu-DOTA-TATE, an SSTR2-targeted ligand, is clinically used for therapy in patients with NETs; however, a low-absorbed dose in tumors remains a limitation...Among them, [111In]-In-TATE-DA-I showed the highest tumor AUC value and clearly visualized the SSTR2-positive tumor in SPECT/CT imaging. These findings highlight the importance of structural modification in the ALB moiety to enhance tumor accumulation of DOTA-TATE-based radioligands.

Patients treated with everolimus had a median PFS of 5 (95% CI: 0.3-10) months, and chemotherapy with streptozocin and 5-fluorouracil resulted in a median PFS of 8 (95% CI: 5-11) months. Re-introduction of PRRT with 2 additional cycles had reduced efficacy compared with the initial treatment. PFS was short in non-somatostatin receptor-based therapies like everolimus and chemotherapy.

Despite these developments, the optimal combination of radionuclide therapy with redifferentiation strategies, multikinase inhibitors, and gene-targeted treatments remains unclear. This review brings together current and emerging treatment approaches for radioiodine-refractory thyroid cancer and discusses how theranostics may become part of routine care.

P1, N=24, Recruiting, Peking University Cancer Hospital & Institute

SSTR PET/CT enables high-contrast meningioma visualisation. [18F]AlF-NOTA-octreotide seems clinically interchangeable with gallium-68-labelled tracers, while offering logistical advantages. PRRT achieves meaningful disease stabilisation, supporting further validation in prospective randomised studies.

The theranostic platform enables both precise visualization and targeted radionuclide therapy. Prospective multicenter trials with standardized protocols are essential to establish evidence-based clinical guidelines.

This review summarises clinical evidence, translational advances, and future perspectives for PRRT as a cornerstone of precision nuclear oncology. Emphasis is placed on expanding indications, integrating α-emitters, improving safety and dosimetry, and developing novel theragnostic ligands that enable personalised treatment strategies for NETs patients.

P2, N=11, Active, not recruiting, Advanced Accelerator Applications | Trial completion date: May 2034 --> Feb 2034

Our findings demonstrate that during ligand binding or G protein coupling, the labeled site on transmembrane helix 6 (TM6) of SSTR3 progressively becomes exposed to the extracellular environment and exhibits increased dynamical characteristics. Our work provides structural and dynamic insights that will facilitate the rational design of subtype-selective drugs targeting SSTRs and possessing improved therapeutic profiles.

Outcomes were numerically more favorable in individuals with high SSTR uptake and in those treated with tandem therapy, but the study was not designed to compare treatment regimens. These exploratory findings should be regarded as hypothesis-generating only and do not provide evidence of comparative efficacy.